Nubeqa FDA Approval History
Last updated by Judith Stewart, BPharm on Nov 29, 2019.
Nubeqa (darolutamide) is an androgen receptor inhibitor (ARi) indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).
Development Timeline for Nubeqa
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.